![]() |
市场调查报告书
商品编码
1408981
全球糖尿病视网膜病变市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
预计到 2030 年,全球糖尿病视网膜病变市场的市场规模将从 2022 年的 86.1 亿美元达到近 150.8 亿美元,2023-2030 年研究期间CAGR为 7.26%。
糖尿病视网膜病变是一种与糖尿病相关的眼部疾病,会影响视网膜(眼睛后部的感光组织)。它是糖尿病患者视力障碍的一个主要原因。随着与糖尿病相关的血糖水平升高对视网膜内的小血管造成损害,这种情况逐渐发展。
糖尿病视网膜病变市场由几个关键因素驱动,其中全球糖尿病盛行率不断上升是主要原因。由于糖尿病仍然是一个重大的健康问题,发病率的上升导致越来越多的人面临糖尿病视网膜病变的风险,从而推动了对诊断和治疗解决方案的需求。诊断工具和影像技术的技术进步对增强早期检测能力的贡献显而易见。对定期眼部筛检的重视以及将远距医疗纳入筛检计画进一步扩大了可近性,特别是在服务不足的地区。药物创新,包括玻璃体内注射和针对糖尿病黄斑水肿的药物,透过提供有效的管理选择,促进市场的发展。医疗保健专业人员和患者对眼睛健康在糖尿病管理中的重要性的认识不断提高,鼓励增加筛检和早期介入。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外,这些工具也对全球糖尿病视网膜病变市场的各个细分市场进行了包容性评估。糖尿病视网膜病变产业的成长和趋势为本研究提供了整体方法。
本节涵盖区域前景,重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲糖尿病视网膜病变市场当前和未来的需求。此外,该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。糖尿病视网膜病变市场的主要参与者包括拜耳公司、艾伯维公司、诺华公司、Oxurion NV、Sirnaomics、Alimera Sciences、Ampio Pharmaceuticals Inc.、BCNPeptides、Kowa Company Ltd.和Genentech, Inc.。查看竞争格局,包括各种策略发展,例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。
如果您有任何客製化要求,请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
The global demand for Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.08 BN by 2030 from USD 8.61 BN in 2022 with a CAGR of 7.26% under the study period 2023 - 2030.
Diabetic retinopathy is an eye disease linked to diabetes, impacting the retina-the light-sensitive tissue at the back of the eye. It stands as a prominent cause of vision impairment among individuals with diabetes. The condition develops gradually as elevated levels of blood sugar associated with diabetes cause damage to the small blood vessels within the retina.
The diabetic retinopathy market is driven by several key factors, with the increasing global prevalence of diabetes being a primary contributor. As diabetes remains a significant health concern, the rising incidence contributes to a growing population at risk of diabetic retinopathy, propelling the demand for diagnostic and treatment solutions. The pivotal role of technological advancements in diagnostic tools and imaging techniques is evident in their contribution to enhancing early detection capabilities. The emphasis on regular eye screenings and the integration of telemedicine in screening programs further expands accessibility, particularly in underserved areas. Pharmaceutical innovations, including intravitreal injections and medications targeting diabetic macular edema, contribute to the market's development by offering effective management options. The heightened awareness among healthcare professionals and patients about the importance of eye health in diabetes management encourages increased screenings and early intervention.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic retinopathy. The growth and trends of diabetic retinopathy industry provide a holistic approach to this study.
This section of the diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Diabetic Retinopathy market include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., and Genentech, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.